Gliptins have been shown to be safe (by 3P/4P MACE) in patients with history of CVD or at risk of CVD. HHF cannot be considered a class effect. Positive impact with gliptins has been noted on urinary albumin excretion in SAVOR, TECOS and CARMELINA. Sitagliptin and linagliptin seem to be equally similar and CV safe on all hard endpoints (Robust CV safety).